Ionis Pharmaceuticals, Inc. (IONS) Analysts See $0.04 EPS; Credit Agricole S A Has Lifted Infosys LTD (INFY) Position By $2.42 Million

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Logo

Analysts expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report $0.04 EPS on February, 26.They anticipate $0.02 EPS change or 100.00% from last quarter’s $0.02 EPS. IONS’s profit would be $5.50 million giving it 367.06 P/E if the $0.04 EPS is correct. After having $-0.03 EPS previously, Ionis Pharmaceuticals, Inc.’s analysts see -233.33% EPS growth. The stock increased 1.21% or $0.7 during the last trading session, reaching $58.73. About 596,885 shares traded. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has risen 1.50% since February 10, 2018 and is uptrending. It has outperformed by 1.50% the S&P500. Some Historical IONS News: 20/04/2018 – Biogen Will Have First Choice of Neurology Targets on Which to Exclusively Collaborate With Ionis; 26/03/2018 – IONIS SAYS INOTERSEN TRIAL SHOWS CONTINUED `SUSTAINED BENEFIT’; 09/04/2018 – IONIS EARNS $30M LICENSE FEE FOR IONIS-AZ6-2.5-L RX; 15/03/2018 – Ionis and Akcea Partner to Commercialize lnotersen for hATTR; 17/04/2018 – Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for HATTR; 15/03/2018 – AKCEA THERAPEUTICS INC – CO TO HAVE RIGHTS TO COMMERCIALIZE INOTERSEN AND AKCEA-TTR-L(RX )GLOBALLY; 24/04/2018 – BIOGEN INC – QTRLY SPINRAZA REVENUE OF $364 MLN VS $47 MLN REPORTED LAST YEAR; 11/05/2018 – $AKCA +20% $IONS +5%; 09/04/2018 – Ionis: IONIS-AZ6-2.5-L Is Designed to Inhibit Undisclosed Target to Treat Patients With Nonalcoholic Steatohepatitis; 23/04/2018 – Biogen: Later-Onset Spinal Muscular Atrophy Patients Treated With Spinraza Walked Longer Distances While Experiencing Stable or Less Fatigue Over Time

Credit Agricole S A increased Infosys Ltd (INFY) stake by 100.42% reported in 2018Q3 SEC filing. Credit Agricole S A acquired 241,796 shares as Infosys Ltd (INFY)’s stock declined 7.54%. The Credit Agricole S A holds 482,592 shares with $4.91 million value, up from 240,796 last quarter. Infosys Ltd now has $45.95B valuation. The stock increased 0.09% or $0.01 during the last trading session, reaching $10.86. About 4.10M shares traded. Infosys Limited (NYSE:INFY) has risen 22.14% since February 10, 2018 and is uptrending. It has outperformed by 22.14% the S&P500. Some Historical INFY News: 13/04/2018 – INDIA’S INFOSYS’ EXEC SAYS CO EXPLORING POTENTIAL BUYERS FOR SUBSIDIARIES INCLUDING SKAVA AND PANAYA; 15/03/2018 – INFOSYS TO CONSIDER FY18 RESULTS ON APRIL 12-13; 13/04/2018 – INFOSYS- IDENTIFIED AMOUNT OF UP TO ABOUT 104 BLN RUPEES TO BE PAID OUT TO SHAREHOLDERS FOR FINANCIAL YEAR 2019; 13/04/2018 – INFOSYS LTD INFY.NS – APPROVED AGREEMENT TO ACQUIRE WONGDOODY HOLDING CO FOR TOTAL CONSIDERATION OF UP TO $75 MLN; 13/04/2018 – INFOSYS TO PAY INR10 AS SPECIAL DIVIDEND; 26/05/2018 – Infosys Limited – General announcement; 13/04/2018 – INFOSYS- CO INITIATED IDENTIFICATION, EVALUATION OF POTENTIAL BUYERS FOR UNITS KALLIDUS AND SKAVA AND PANAYA; 17/04/2018 – New Infosys CEO Says Now Is Time to Sacrifice Margins for Growth; 08/03/2018 – INFOSYS LTD INFY.NS CLARIFIES ON NEWS ITEM ON CO, l-T OFFICIALS UNDER CBI SCANNER; 08/03/2018 – INFOSYS LTD INFY.NS SAYS CO NOT NAMED AS ACCUSED PARTY IN THE FIR

More recent Infosys Limited (NYSE:INFY) news were published by: Streetinsider.com which released: “Molina Healthcare (MOH) Announces Agreement with Infosys (INFY) to Improve Information Technology Infrastructure – StreetInsider.com” on February 06, 2019. Also Economictimes.Indiatimes.com published the news titled: “Infy’s strong Q3, buyback likely to trip short sellers – Economic Times” on January 14, 2019. Prnewswire.com‘s news article titled: “EdgeVerve Systems Launches AssistEdge Discover to Unlock the True Value of Automation – PRNewswire” with publication date: January 22, 2019 was also an interesting one.

Among 4 analysts covering Infosys (NYSE:INFY), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Infosys had 4 analyst reports since September 14, 2018 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Neutral” on Friday, September 14. The stock of Infosys Limited (NYSE:INFY) earned “Neutral” rating by Goldman Sachs on Wednesday, October 17. The company was maintained on Tuesday, November 27 by Wedbush. The stock of Infosys Limited (NYSE:INFY) has “Neutral” rating given on Monday, January 14 by Susquehanna.

Credit Agricole S A decreased Amazon Com Inc (Put) (NASDAQ:AMZN) stake by 15,568 shares to 2,500 valued at $5.01M in 2018Q3. It also reduced Fedex Corp (NYSE:FDX) stake by 10,590 shares and now owns 40,580 shares. Berkshire Hathaway Inc Del (BRKB) was reduced too.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: Nasdaq.com which released: “Has Ionis Pharmaceuticals (IONS) Outpaced Other Medical Stocks This Year? – Nasdaq” on January 28, 2019, also Benzinga.com with their article: “Ionis (NASDAQ:IONS) Wins Price Target Hike On Partner Biogen’s Guidance (NASDAQ:BIIB) – Benzinga” published on January 30, 2019, Nasdaq.com published: “J&J, plaintiffs ‘close’ to deal on Pinnacle hip implant lawsuits: lawyer – Nasdaq” on February 04, 2019. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: Fool.com and their article: “3 Top Biotech Stocks to Buy in January – The Motley Fool” published on January 12, 2019 as well as Nasdaq.com‘s news article titled: “Ironwood Commences Phase I Study on IW-6463 for CNS Disorders – Nasdaq” with publication date: January 24, 2019.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company has market cap of $8.08 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart